A Study to Evaluate Zoledronic Acid for Fracture Prevention in Parkinson's Disease Patients

Overview

Información sobre este estudio

The purpose of this study is to evaluate the use of a single infusion of zoledronic acid-5 mg (ZA) vs. placebo for the prevention of fractures in men and women aged 65 years and older with Parkinson's Disease with 2 years of follow-up.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Men and women age 65 years or older.
  • Current PD diagnosis with symptoms severity at Hoehn & Yahr (H&Y) stage 1-4 based on an expert assessment (movement disorders neurologist report or telemedicine evaluation).
  • Willing and able to continue in follow-up for at least 2 years.
  • Willing and able to provide informed consent.

Exclusion Criteria:

  • History of hip fracture.
  • Any use of a bisphosphonate drug within the last 12 months.
  • Use of any other osteoporosis treatment (such as SERMs and denosumab) within the last 6 months.
  • Tooth extraction or invasive dental procedures within the past 30 days or planned/scheduled extraction/procedure in the next 12 months.
  • Non-ambulatory; i.e., unable to walk without assistance of another person.
  • Undergoing kidney dialysis.
  • A diagnosis of multiple myeloma or Paget's disease.
  • Unable to speak or read English sufficiently to complete informed consent.
  • Any other criteria, which would make the patient unsuitable to participate in this study as determined by the study staff (e.g., an uncontrolled drug and/or alcohol addiction).

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Matthew Drake, M.D., Ph.D.

Abierto para la inscripción

Contact information:

Vishakantha Murthy Ph.D., M.B.A., CCRP

(919) 265-9986

Murthy.Vishakantha@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20509162

Mayo Clinic Footer